Preventing Childhood Obesity - Evidence Policy and Practice.pdf
Preventing Childhood Obesity - Evidence Policy and Practice.pdf
Preventing Childhood Obesity - Evidence Policy and Practice.pdf
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Chapter 2<br />
trade. There are provisions that allow public health<br />
concerns to “ override ” the desire for more free trade<br />
in the WTO but the drawbacks of relying upon WTO<br />
exemptions include economic disincentives associated<br />
with violation of WTO rules that may prevent States<br />
from giving priority to public health when conflicts<br />
arise, <strong>and</strong> may also impede the negotiation, ratification<br />
<strong>and</strong> implementation of international public<br />
health instruments.<br />
Optimize e ffectiveness (in t erms<br />
of q uality <strong>and</strong> c overage) of<br />
e xisting e fficacious i nterventions<br />
e specially in h ealth s ector<br />
There are a number of efficacious <strong>and</strong> effective interventions<br />
that can prevent or reduce the morbidity<br />
<strong>and</strong> mortality associated with non - communicable<br />
diseases. However, too often, the inverse care law<br />
applies in terms of the coverage of these interventions:<br />
those who need the interventions the most are<br />
the least likely to receive them. Within countries, there<br />
are differences in coverage between the rich <strong>and</strong><br />
poor <strong>and</strong> between urban <strong>and</strong> rural areas. There are<br />
also large differences in access to care between<br />
countries.<br />
Unfortunately, the evidence for what works in<br />
terms of scaling up interventions for non - communicable<br />
diseases is limited. Reviews of relatively successful<br />
non - communicable disease programmes have<br />
highlighted some common features including: routine<br />
patient monitoring; shared decision making between<br />
health professionals <strong>and</strong> patients; self - management<br />
support that allow patients to successfully manage<br />
their symptoms, treatments <strong>and</strong> preventive health<br />
behaviors on a day - to - day basis; <strong>and</strong> community<br />
linkages that allow interventions such as population -<br />
based health promotion <strong>and</strong> disease prevention,<br />
integration of people with NCDs into community life,<br />
<strong>and</strong> provision of complementary <strong>and</strong> home - based<br />
health services. 13 However, nearly all these lessons are<br />
based on non - communicable care models in the USA<br />
or UK with very little evidence of what works at scale<br />
in resource - poor settings. The approach of WHO with<br />
regards to the non - communicable care <strong>and</strong> treatment<br />
of people living with HIV/Aids is interesting in that<br />
it focuses on a slightly different set of principles<br />
(Box 2.2 ).<br />
Box 2.2 Scaling up HIV t reatment<br />
The huge burden of unmet care <strong>and</strong> treatment for HIV<br />
has led to a plethora of treatment options for those<br />
infected, especially in Southern Africa where the epidemic<br />
is at its worst. Difficulty in accessing efficacious<br />
drug treatments has led many HIV patients to spend<br />
significant amounts of resources in accessing sub -<br />
st<strong>and</strong>ard care <strong>and</strong> treatment. Governments <strong>and</strong> agencies<br />
are now responding by scaling up the introduction<br />
of long - term treatment of HIV with the provision of<br />
anti - retroviral treatment ( ART ). The challenges of providing<br />
non - communicable care in the context of weak<br />
health systems have led WHO to adopt what they<br />
termed a “ public - health approach to ART treatment ” .<br />
A number of innovations marked a shift from previous<br />
attempts to provide ART:<br />
1) st<strong>and</strong>ardization of first - line <strong>and</strong> second - line treatment<br />
along with a prescriptive approach, facilitating<br />
the development of fixed - dose first line combinations,<br />
<strong>and</strong> driving down the price of these drugs;<br />
2) simplification of clinical decision making with an<br />
attempt to manage without necessarily having any<br />
immunological monitoring;<br />
3) decentralization of treatment to the district level<br />
through the development <strong>and</strong> training in adapted<br />
integrated management of adult illness (IMAI)<br />
guidelines;<br />
4) task shifting of essential activities such as initiation<br />
<strong>and</strong> monitoring of treatment from physicians to<br />
nurses;<br />
5) procurement <strong>and</strong> supply management strengthening,<br />
with a focus on reducing the number of commodities<br />
<strong>and</strong> drugs <strong>and</strong> being more specific of<br />
exact requirements. Such an approach has allowed<br />
a significant scaling up of the provision of ART <strong>and</strong><br />
early results suggest that while early mortality is<br />
high the medium - term outcomes for those on the<br />
programmes is good. 14<br />
Decentralized c are f ocused at the<br />
p rimary h ealth c are l evel<br />
The example of the scale - up of treatment for HIV/<br />
Aids emphasizes the shift in the care of patients from<br />
specialists <strong>and</strong> hospitals to nurse - led care at a primary<br />
health care center. There is now good evidence from<br />
well resourced settings that primary - care - led patient<br />
models can lead to similar <strong>and</strong> often better outcomes<br />
than specialist, tertiary level care. There is also some<br />
18